Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma

Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting for 7.5 to 8.7% of CRCs. It has been shown that SAC has a poorer prognosis and has different molecular and immunohistochemical features compared with conventional carcinoma (CC) but, to date, only one previous study has analyzed its mRNA expression profile by microarray. Using a different microarray platform, we have studied the molecular signature of 11 SACs and compared it with that of 15 matched CC with the aim of discerning the functions which characterize SAC biology and validating, at the mRNA and protein level, the most differentially expressed genes which were also tested using a validation set of 70 SACs and 70 CCs to assess their diagnostic and prognostic values. Microarray data showed a higher representation of morphogenesis‐, hypoxia‐, cytoskeleton‐ and vesicle transport‐related functions and also an overexpression of fascin1 (actin‐bundling protein associated with invasion) and the antiapoptotic gene hippocalcin in SAC all of which were validated both by quantitative real‐time PCR (qPCR) and immunohistochemistry. Fascin1 expression was statistically associated with KRAS mutation with 88.6% sensitivity and 85.7% specificity for SAC diagnosis and the positivity of fascin1 or hippocalcin was highly suggestive of SAC diagnosis (sensitivity = 100%). Evaluation of these markers in CRCs showing histological and molecular characteristics of high‐level microsatellite instability (MSI‐H) also helped to distinguish SACs from MSI‐H CRCs. Molecular profiling demonstrates that SAC shows activation of distinct signaling pathways and that immunohistochemical fascin1 and hippocalcin expression can be reliably used for its differentiation from other CRC subtypes.

[1]  P. Conesa‐Zamora,et al.  Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI‐H carcinomas , 2012, International journal of cancer.

[2]  P. Conesa‐Zamora,et al.  Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma. , 2012, Human pathology.

[3]  P. Conesa‐Zamora,et al.  Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma , 2011, Histopathology.

[4]  H. Friess,et al.  Reduced α-dystroglycan expression correlates with shortened patient survival in pancreatic cancer. , 2011, The Journal of surgical research.

[5]  Gemma Navarro,et al.  Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jean Jakoncic,et al.  Migrastatin analogues target fascin to block tumour metastasis , 2011, Nature.

[7]  F. Eggeling,et al.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases , 2011, Clinical & Experimental Metastasis.

[8]  M. Mäkinen,et al.  Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma , 2011, Histopathology.

[9]  M. O'brien,et al.  The Clinical Significance of Serrated Polyps , 2011, The American Journal of Gastroenterology.

[10]  Payal Sipahimalani,et al.  A Histology-Based Model for Predicting Microsatellite Instability in Colorectal Cancers , 2010, The American journal of surgical pathology.

[11]  P. Conesa‐Zamora,et al.  Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. , 2010, Human pathology.

[12]  Xin-Yun Huang,et al.  Migrastatin Analogues Target Fascin to Block Tumor Metastasis , 2010, Nature.

[13]  W. Frankel,et al.  Colorectal Cancer Due to Deficiency in DNA Mismatch Repair Function: A Review , 2009, Advances in anatomic pathology.

[14]  D. Qualtrough,et al.  The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro , 2009, British Journal of Cancer.

[15]  M. Breslin,et al.  Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  S. Gruber,et al.  Pathologic Predictors of Microsatellite Instability in Colorectal Cancer , 2009, The American journal of surgical pathology.

[17]  M. Redston CHAPTER 23 – Epithelial Neoplasms of the Large Intestine , 2009 .

[18]  Joaquín Dopazo,et al.  Babelomics: advanced functional profiling of transcriptomics, proteomics and genomics experiments , 2008, Nucleic Acids Res..

[19]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[20]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[21]  L. Aaltonen,et al.  Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis , 2007, Oncogene.

[22]  M. Mäkinen,et al.  Colorectal serrated adenocarcinoma , 2007, Histopathology.

[23]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[24]  Josephine C. Adams,et al.  Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas , 2006, BMC Cancer.

[25]  A. Liakka,et al.  Morphology and microsatellite instability in sporadic serrated and non‐serrated colorectal cancer , 2005, The Journal of pathology.

[26]  Josephine C. Adams,et al.  Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? , 2005, The international journal of biochemistry & cell biology.

[27]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[28]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[29]  A. Tepikin,et al.  Dynamics and calcium sensitivity of the Ca2+/myristoyl switch protein hippocalcin in living cells , 2003, The Journal of cell biology.

[30]  M. Sasaki,et al.  Aberrantly expressed recoverin is functionally associated with G-protein-coupled receptor kinases in cancer cell lines. , 2002, Biochemical and biophysical research communications.

[31]  Josephine C. Adams,et al.  Fascins, and their roles in cell structure and function. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  P. Vihko,et al.  Colorectal carcinoma associated with serrated adenoma – prevalence, histological features, and prognosis , 2001, The Journal of pathology.

[33]  J. Kukkonen,et al.  NAIP interacts with hippocalcin and protects neurons against calcium‐induced cell death through caspase‐3‐dependent and ‐independent pathways , 2000, The EMBO journal.

[34]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[35]  K. Takamatsu,et al.  Myristoylation of hippocalcin is linked to its calcium-dependent membrane association properties. , 1993, The Journal of biological chemistry.

[36]  T. Katsuyama,et al.  MUGOSUBSTANCE HISTOCHEMISTRY OF THE NORMAL MUCOSA and EPITHELIAL NEOPLASMS OF THE LARGE INTESTINE , 1985, Acta pathologica japonica.

[37]  J. Burke,et al.  Carcinoma of the colon and rectum. , 1962, The New England journal of medicine.

[38]  G. Miller Carcinoma of the Colon and Rectum. , 1942, Canadian Medical Association journal.